Trimble Edward L, Thompson Sharon, Christian Michaele C, Minasian Lori
Division of Cancer Treatment and Diagnosis, National Cancer Institute, 6130 Executive Boulevard, Suite 7025, MSC 7436, Bethesda, Maryland 20892-7436, USA.
Oncologist. 2008 Apr;13(4):403-9. doi: 10.1634/theoncologist.2007-0058.
In 2006, i.p. chemotherapy re-emerged as a controversial topic in debates about the optimal treatment for women with advanced epithelial ovarian cancer. In this paper, we address the rationale behind i.p. chemotherapy, the data supporting its use, the selection of appropriate patients for i.p. chemotherapy, how best to avoid and manage the toxicities observed with i.p. chemotherapy, and directions for future research.
2006年，腹腔化疗在关于晚期上皮性卵巢癌女性最佳治疗方案的讨论中再度成为一个有争议的话题。在本文中，我们阐述了腹腔化疗背后的基本原理、支持其应用的数据、腹腔化疗合适患者的选择、如何最好地避免和处理腹腔化疗中观察到的毒性，以及未来的研究方向。
